As mice in both of the aforementioned obesity studies [20,21] were treated with SGLT2 inhibitors for a longer time than the BPH/2J mice were in our study, we hypothesize that extending our time course of treatment may potentially also enhance the beneficial effects of Dapagliflozin. This evidence concerns the gene SLC5A2 and obesity disorder.